Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study

The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with en...

Descripción completa

Detalles Bibliográficos
Autores principales: Emons, Günther, Tempfer, Clemens, Battista, Marco Johannes, Mustea, Alexander, Vordermark, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195428/
https://www.ncbi.nlm.nih.gov/pubmed/30364421
http://dx.doi.org/10.1055/a-0658-1918
_version_ 1783364393067610112
author Emons, Günther
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
author_facet Emons, Günther
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
author_sort Emons, Günther
collection PubMed
description The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with endometrial cancer and an increased risk of recurrence. With this statement, the Uterus Committee of the Gynaecological Oncology Working Group (AGO) wishes therefore to interpret the new data and discuss them against the background of the new S3 guideline “Diagnosis, treatment and follow-up of patients with endometrial cancer”.
format Online
Article
Text
id pubmed-6195428
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-61954282018-10-22 Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study Emons, Günther Tempfer, Clemens Battista, Marco Johannes Mustea, Alexander Vordermark, Dirk Geburtshilfe Frauenheilkd The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with endometrial cancer and an increased risk of recurrence. With this statement, the Uterus Committee of the Gynaecological Oncology Working Group (AGO) wishes therefore to interpret the new data and discuss them against the background of the new S3 guideline “Diagnosis, treatment and follow-up of patients with endometrial cancer”. Georg Thieme Verlag KG 2018-10 2018-10-19 /pmc/articles/PMC6195428/ /pubmed/30364421 http://dx.doi.org/10.1055/a-0658-1918 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Emons, Günther
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title_full Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title_fullStr Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title_full_unstemmed Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title_short Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
title_sort statement of the uterus committee of the gynaecological oncology working group (ago) on the portec-3 study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195428/
https://www.ncbi.nlm.nih.gov/pubmed/30364421
http://dx.doi.org/10.1055/a-0658-1918
work_keys_str_mv AT emonsgunther statementoftheuteruscommitteeofthegynaecologicaloncologyworkinggroupagoontheportec3study
AT tempferclemens statementoftheuteruscommitteeofthegynaecologicaloncologyworkinggroupagoontheportec3study
AT battistamarcojohannes statementoftheuteruscommitteeofthegynaecologicaloncologyworkinggroupagoontheportec3study
AT musteaalexander statementoftheuteruscommitteeofthegynaecologicaloncologyworkinggroupagoontheportec3study
AT vordermarkdirk statementoftheuteruscommitteeofthegynaecologicaloncologyworkinggroupagoontheportec3study

Ejemplares similares